These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Preprint Version- Article copy.pdf (6.15 MB)

In-silico Studies of Antimalarial-agent Artemisinin and Derivatives Portray More Potent Binding to Lys353 and Lys31-Binding Hotspots of SARS-CoV-2 Spike Protein than Hydroxychloroquine: Potential Repurposing of Artenimol for COVID-19.

submitted on 08.04.2020, 16:33 and posted on 09.04.2020, 13:15 by Moussa SEHAILIA, Smain chemat

The role of hydroxychloroquine to prevent hACE2 from interacting with SARS-CoV-2 Spike protein is unveiled. Artemisinin & derived compounds entangle better than hydroxychloroquine into Lys353 and Lys31 binding hotspots of the virus Spike protein, therefore preventing infection occurs. Since these molecules are effective antivirals with excellent safety track records, their potential repurposing is recommended for clinical trials of COVID-19 patients.


Email Address of Submitting Author


Research centre in Chemical and Physical Analysis (C.R.A.P.C)



ORCID For Submitting Author


Declaration of Conflict of Interest

The authors declare no conflict of interest